Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3

View Full Paper
Ask AI
Bookmark
Share

Authors

WJWojciech JurczakMKMichał KwiatekMMMarie Maerevoet

Discussion

Loading...

Member takes

Overview

Phase 2 trial reports 70% overall response and high MRD-negativity in elderly large B-cell lymphoma patients, suggesting new treatment potential.

Key Points

  • Evaluate the efficacy and safety of epcoritamab monotherapy in elderly patients with newly diagnosed large B-cell lymphoma and comorbidities.
  • Phase 2 trial with two stages; patients received subcutaneous epcoritamab monotherapy
  • Primary endpoint: complete response rate using Lugano criteria
  • Secondary endpoint: minimal residual disease negativity assessed by circulating tumor DNA
  • Overall response rate was 70% with 58% achieving complete response
  • Median progression free survival was 13.0 months
  • 88% of MRD-evaluable responders were reported MRD negative

Cite This Study

Jurczak et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cfd7https://doi.org/10.1182/blood-2025-63
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma2025
  2. 2Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 72025 · 1 citations
  3. 3Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial2025 · 4 citations
  4. 4Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b/2 EPCORE CLL-1 trial2025
  5. 5Durable responses in patients with large B-cell lymphoma and 3+ prior lines of therapy who either paused or discontinued epcoritamab monotherapy while in complete response2025